CD274 and neoplasm: Beside the current treatment landscape in squamous cell cancer of the esophagus combining PD-1/PD-L1 inhibitors with chemotherapy, combinations with targeted agents have shown promising data in other tumor types or have even been approved (e.g., in renal cell or endometrial cancer).